摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-5-(1-ethoxyethenyl)-6-(methoxymethyl)pyrimidin-2-yl]amino]benzonitrile | 1037452-89-3

中文名称
——
中文别名
——
英文名称
4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-5-(1-ethoxyethenyl)-6-(methoxymethyl)pyrimidin-2-yl]amino]benzonitrile
英文别名
——
4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-5-(1-ethoxyethenyl)-6-(methoxymethyl)pyrimidin-2-yl]amino]benzonitrile化学式
CAS
1037452-89-3
化学式
C28H28N6O2
mdl
——
分子量
480.569
InChiKey
BMTPHMAJVGTENE-BQYQJAHWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    36
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    116
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-5-iodo-6-(methoxymethyl)pyrimidin-2-yl]amino]benzonitrile 、 三丁基(1-乙氧基乙烯)锡 在 bis-triphenylphosphine-palladium(II) chloride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以20%的产率得到4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]-5-(1-ethoxyethenyl)-6-(methoxymethyl)pyrimidin-2-yl]amino]benzonitrile
    参考文献:
    名称:
    WO2008/80965
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • HIV inhibiting 5,6-substituted pyrimidines
    申请人:Janssen R&D Ireland
    公开号:EP2781510A1
    公开(公告)日:2014-09-24
    HIV replication inhibitors of formula having HIV (Human Immunodeficiency Virus) replication inhibiting properties, the preparation thereof and pharmaceutical compositions comprising these compounds. In particular the compounds have an improved ability to inhibit the replication of mutant strains, in particular of strains that have become resistant to one or more known NNRTI drugs, which strains are referred to as drug- or multidrug-resistant HIV strains
    艾滋病毒复制抑制剂配方 具有抑制 HIV(人类免疫缺陷病毒)复制的特性,其制备方法以及包含这些化合物的药物组合物。特别是,这些化合物对突变株,尤其是对一种或多种已知 NNRTI 药物产生耐药性的菌株(这些菌株被称为耐药或耐多药 HIV 菌株)的复制具有更好的抑制能力。
  • HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES
    申请人:Janssen R&D Ireland
    公开号:EP2114902B1
    公开(公告)日:2014-09-17
  • HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES
    申请人:Guillemont Jerôme Emile Georges
    公开号:US20100261722A1
    公开(公告)日:2010-10-14
    HIV replication inhibitors of formula R 1 is hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; C 1-6 alkyloxycarbonyl; R 2 , R 3 , R 7 and R 8 are hydrogen; hydroxy; halo; C 3-7 cycloalkyl; C 1-6 alkyloxy; carboxyl; C 1-6 alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C 1-6 alkyl)amino; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; —C(═O)R 10 ; C 1-6 alkyl optionally substituted with halo, cyano or —C(═O)R 10 ; optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl; R 4 and R 9 are hydroxy; halo; C 3-7 cycloalkyl; C 1-6 alkyloxy; carboxyl; C 1-6 alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C 1-6 alkyl)amino; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; —C(═O)R 10 ; cyano; —S(═O) r R 10 ; —NH—S(═O) 2 R 10 ; —NHC(═O)H; —C(═O)NHNH 2 ; —NHC(═O)R 10 ; Het; —Y-Het; optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; R 5 is C 2-6 alkenyl or C 2-6 alkynyl both substituted with cyano, aminocarbonyl, mono- and di(C 1-6 alkyl)aminocarbonyl, aryl, pyridyl, thienyl, furanyl, or with one or two C 1-6 alkyloxy groups; Het; —C(═O)NR 5a R 5b ; —CH(OR 5c )R 5d ; X is —NR 1 —, —O—, —CH 2 —, or —S—; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
  • US8318736B2
    申请人:——
    公开号:US8318736B2
    公开(公告)日:2012-11-27
  • [EN] HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES<br/>[FR] PYMIRIDINES SUBSTITUÉES EN 5,6, INHIBITRICES DU VIH
    申请人:TIBOTEC PHARM LTD
    公开号:WO2008080965A2
    公开(公告)日:2008-07-10
    [EN] R1 is hydrogen; aryl; formyl; C1_6alkylcarbonyl; C1_6alkyl; C1_6alkyloxycarbonyl; R2, R3, R7 and R8 are hydrogen; hydroxy; halo; C3-7cycloalkyl; C1_6alkyloxy; carboxyl; C1_6alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C1_6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; -C(=O)R10; C1_6alkyl optionally substituted with halo, cyano or -C(=O)R10; optionally substituted C1_6alkyl, C2-6alkenyl, or C2-6alkynyl; R4 and R9 are hydroxy; halo; C3_7Cycloalkyl; C1_6alkyloxy; carboxyl; C1_6alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C1_6alkyl)amino; polyhaloC1_6alkyl; polyhaloC1_6alkyloxy; -C(=O)R10; cyano; -S(=O)rR10; -NH-S(=O)2R10; -NHC(=O)H; -C(=O)NHNH2; -NHC(=O)R10; Het; -Y-Het; optionally substituted C1_6alkyl, C2-6alkenyl or C2-6alkynyl; R5 is C2-6alkenyl or C2-6alkynyl both substituted with cyano, aminocarbonyl, mono- and di(C1_6alkyl)aminocarbonyl, aryl, pyridyl, thienyl, furanyl, or with one or two C1_6alkyloxy groups; Het; -C(=O)NR5aR5b; -CH(OR5c)R5d; X is -NR1-, -O-, -CH2-, or -S-; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
    [FR] L'invention porte sur la formule d'un inhibiteur de la réplication du VIH dans laquelle:R1 est hydrogène; aryle; foumyle; C1_6alkylcarbonyle; C1_6alkyle; C1_6alkyloxycarbonyle; R2, R3, R7 et R8 sont hydrogène; hydroxy; halo; C3-7cycloalkyle; C1_6alkyloxy; carboxyle; C1_6alkyloxycarbonyle; cyano; nitro; amino; mono- ou di(C1_6alkyl)amino; polyhaloC1-6alkyle; polyhaloC1-6alkyloxy; -C(=O)R10; C1_6alkyle facultativement substitué par halo, cyano ou -C(=O)R10; facultativement substitué par C1_6alkyle, C2-6alcényle, ou C2-6alkynyle; R4 et R9 sont hydroxy; halo; C3_7Cycloalkyle; C1_6alkyloxy; carboxyle; C1_6alkyloxycarbonyle; formyle; cyano; nitro; amino; mono- ou di(C1_6alkyl)amino; polyhaloC1_6alkyle; polyhaloC1_6alkyloxy; -C(=O)R10; cyano; -S(=O)rR10; -NH-S(=O)2R10; -NHC(=O)H; -C(=O)NHNH2; -NHC(=O)R10; Het; -Y-Het; facultativement substitué C1_6alkyle, C2-6alcényle ou C2-6alkynyle; R5 est C2-6alcényle ou C2-6alkynyle tous deux substitués par cyano, aminocarbonyle, mono- et di(C1_6alkyl)aminocarbonyle, aryle, pyridyle, thiényle, furanyle, ou par un ou deux groupes C1_6alkylyoxy; Het; -C(=O)NR5aR5b; -CH(OU5c)R5d; X is -NR1-, -O-, -CH2-, ou -S-; L'invention porte aussi sur des préparations pharmaceutiques contenant ces composés dont ils sont le principe actif, et sur les procédés de préparation desdits composés et desdites compositions.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐